

IntechOpen

Drug Discovery and Development

From Molecules to Medicine

Edited by Omboon Vallisuta and Suleiman Olimat



WEB OF SCIENCE™

Copyright material

Drug Discovery and Development - From Molecules to Medicine

<http://dx.doi.org/10.5772/58659>

Edited by Omboon Vallisuta and Suleiman Olimat

Contributors

Elizabeth Hong-Geller, Taosheng Chen, Sergio C. Chai, Asli Nur Goktug, Degenhard Marx, Matthias Birkhoff, Gerallt Williams, Samuel Constant, Christophe Mas, Ken Yasukawa, Charles Malemud, Pawel Kafarski, Magdalena Lipok, Carsten Wrenger, Bjoern Windshuegel, Thales Kronenberger, Oliver Keminer, Terry Smith, Simon Alan Young, Hendrik-Tobias Arkenau, Mark Voskoboynik, Henrik-Tobias Arkenau, Ibrahim Jantan, Adriana Ceci, Viviana Giannuzzi, Lucia Ruggieri, Donato Bonifazi, Mariagrazia Felisi, Martina Smolic

Published by InTech

Janeza Trdine 9, 51000 Rijeka, Croatia

Copyright © 2015 InTech

Individual chapters are under their authors' copyright and distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published chapters provided that the authors and publisher are properly credited, which ensures maximum dissemination and a wider impact of the authors' work. Any republication, referencing or personal use of the individual chapters or any of their contents must explicitly identify the original source.

Permission for commercial use of the book as a whole, such as (but not limited to) reprint rights, republication, distribution, sales, translation, and reproduction in any and all forms of media, must always be obtained from InTech.

Notice

Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book.

Publishing Process Manager Iva Lipovic

Technical Editor InTech DTP team

Cover InTech Design team

First published May, 2015

Printed in Croatia

Additional hard copies can be obtained from orders@intechopen.com

Drug Discovery and Development - From Molecules to Medicine, Edited by Omboon Vallisuta and Suleiman Olimat

p. cm.

ISBN 978-953-51-2128-2

World's largest Science, Technology & Medicine Open Access book publisher.
Publish, read & share novel research.

- [Home](#)
- [Subjects](#)

[Physical Sciences, Engineering and Technology](#)

[Chemistry](#), [Computer and Information
Science](#), [Earth and Planetary Sciences](#),
[Engineering](#), [Materials Science](#),
[Mathematics](#), [Nanotechnology](#) and
[Nanomaterials](#), [Physics](#), [Robotics](#),
[Technology](#).

[Life Sciences](#)

[Agricultural and Biological Sciences](#),
[Biochemistry, Genetics and Molecular
Biology](#), [Environmental Sciences](#),
[Immunology and Microbiology](#),
[Neuroscience](#)

[Health Sciences](#)

[Medicine](#), [Pharmacology, Toxicology
and Pharmaceutical Science](#), [Veterinary
Medicine and Science](#)

[Social Sciences and Humanities](#)

[Business, Management and
Economics](#)

[Psychology](#)

[Social Sciences](#)

[All Books](#)

[Journals Archive](#)

[Open For Submission](#)

<https://www.intechopen.com/books/drug-discovery-and-development-from-molecules-to-medicine/intranasal-drug-administration-an-attractive-delivery-route-for-some->

Read, Share and
Download for FREE

- [Books](#)
- [About Open Access](#)
- [Publish with us](#)
- [News](#)
- [Author Panel Sign In](#) ▼

-
-
-

[Forgot password?](#)

[Pharmacology, Toxicology and Pharmaceutical Science](#) » [Drug Discovery](#) » "[Drug Discovery and Development - From Molecules to Medicine](#)", book edited by Omboon Vallisuta and Suleiman Olimat, ISBN 978-953-51-2128-2, Published: June 3, 2015 under [CC BY 3.0 license](#). © The Author(s).

Chapter 13 OPEN ACCESS

Intranasal Drug Administration — An Attractive Delivery Route for Some Drugs

By Degenhard Marx, Gerallt Williams and Matthias Birkhoff
DOI: 10.5772/59468

- [Read Chapter](#)
- [Author Details](#)
- [Chapter Statistics](#)
- [How To Link and Reference](#)
- [References](#)
- [Citations](#)

Share this page

- [Facebook](#)
- [Twitter](#)
- [Show thumbnails](#) Show tables Show equations [Article top](#)
- [Bibsonomy](#)
- [CiteULike](#)
- [LinkedIn](#)
- [Google+](#)



Figure 1. Multi-dose spray pumps can be fitted onto the bottles using a crimp ferrule, screwed-on or simply snapped on (from left to the right). In the forefront different types of nasal spray actuators.

[2. Evolution of multi-dose spray pumps](#)



Figure 2. Components of a typical multi dose pump. For a fully functional system a dip tube, fixture and actuator need to be added.

[3. A short introduction on intranasal administration](#)



Figure 3. Anatomy of the nasal cavity.

[4. Which technology is on the market?](#)



Figure 4. Spray tips for syringes which are used for the intranasal administration of naloxone, midazolam or some influenza vaccines.



Figure 5. Examples of unit/bidose systems for liquids on the left with a glass vial which contains the one or two doses of the drug product and dry powder devices on the right.

[4.1. Bottles](#)

[5. First steps to identify the right delivery system](#)

[6. Formulation development](#)

[7. Performance parameters](#)




Figure 6. Typical display from a spray pattern test using laser imaging, which can give information about the ovality of the emitted spray.




Figure 7. Typical display from a spray angle test using laser imaging, which can give information about the angle of the emitted spray.

[8. Trends for nasal drug administration](#)

[8.1. Use of preservatives in multi-dose products](#)

[8.2. Non-aqueous nasal formulations](#)

[8.3. Side actuated spray pumps](#)



Figure 8. Example of a side actuated multi-dose spray pump

[8.4. Unit- and bi-dose sprayer](#)

[9. Conclusion](#)

Intranasal Drug Administration — An Attractive Delivery Route for Some Drugs

Degenhard Marx¹, Gerallt Williams² and Matthias Birkhoff¹

^[1] Aptar Radolfzell GmbH, Radolfzell, Germany

^[2] Aptar France SAS, Le Vaudreuil, France

1. Introduction

Intranasal drug administration has a long tradition and was and is still used for medical as well as recreational purposes. The most common use is for treatment of local symptoms e.g. nasal congestion in the course of a common rhinitis or inflammation linked to allergic rhinitis. The medications intended for local activity are well established and can be found across the globe in every pharmacy and drug store. Examples for topical treatment of rhinitis are decongestants (oxymetazoline, xylometazoline, naphazoline), anti-histamines (azelastine, levocabastine, olopatadine) and glucocorticoids (e.g. mometasone, budesonide, fluticasone). For this particular indication, drugs should act fast and only locally while systemic absorption should be as low as possible; this to avoid systemic side effects which are linked with typical oral formulations of comparable drug substances.

As described earlier [1] intranasal administration has much more potential. The nasal mucosa can be used for non-invasive systemic administration of drugs. The surface of the nasal mucosa in humans is around 150 cm², a tissue which is well supplied by blood vessels. This ensures a rapid absorption of most drugs, can generate high systemic blood levels and avoids the first pass metabolism which needs to be taken into account following oral administration. This bypassing of the gastrointestinal system even enables the delivery of peptide hormones [1]. Calcitonin and desmopressin are on the market for years now; insulin and glucagon were under clinical development for this administration route [2].

The rapid absorption of drugs via the nasal mucosa is also utilized for pain medications (e.g. fentanyl nasal sprays), rescue medications like naloxone for opioid overdosing or midazolam for seizures in children. An important aspect for such medications is that intranasal administration is considered a non-invasive administration route and easy to do for self-administration or for care-givers. It has a low potential for injuries or disease transmission (hepatitis B, HIV). This is of special importance if fast relief from severe symptoms is required and patient's ability to deal with injections is impaired. Intranasal triptanes for migraine treatment, fentanyl to stop cancer breakthrough pain and ondansetron to relieve nausea are examples for this trend. For these indications, single dose systems or multi-dose pumps with counting or lock-out mechanisms are available to reduce the risk of unintended overdosing or misuse [1].

Vaccines may also benefit from the intranasal route. Existing vaccines commonly utilize the intramuscular and oral administration route. While the respiratory and gastrointestinal tract is very immune competent and fights with microbes permanently, the muscle is not the first choice. Intramuscular vaccination primarily induces systemic immune response, mainly via formation of vaccine-strain specific circulating antibodies. Injections of vaccines were done since the early days and they are indeed effective. So for most people today vaccination is equal to getting an intramuscular injection which is linked to pain. For the health care professional it is linked to fears of needle stick injuries, risk of disease transmission and dangerous medical waste.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.